Price movement over the last 24 hours
Abbott Laboratories vs Progressive Corp — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while Progressive Corp trades at $232.41 (market cap $136.47B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Progressive Corp pays the higher dividend (5.93%). Which is the better fit depends on your goals.
| ABT | PGR | |
|---|---|---|
Market Cap | $166.94B | $136.47B |
Sector | Health | Financials |
52-Week High | $136.62 | $252.68 |
52-Week Low | $82.57 | $190.40 |
Enterprise Value | $193.69B | $144.69B |
Dividend Yield | 2.63% | 5.93% |
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Progressive (PGR) trades at $234.40, up 0.94% with a bullish technical signal and strong fundamentals. Recent earnings beat expectations with Q1 2026 EPS of $4.96 versus $4.85 estimate, continuing a trend of operational strength. Revenue grew to $87.64B in 2025 with net income margin at 12.93%, while analyst consensus price target is $235.67. The stock shows resilience with positive media coverage highlighting earnings growth and leadership changes.
Outlook remains positive driven by earnings momentum and scale advantages in auto insurance. Key risks include competitive pressures and macroeconomic sensitivity. Institutional sentiment is mixed with 41.46% buy ratings, but the stock's valuation at P/E 11.78 offers room for upside if earnings trends persist.
Trailing returns across standard periods
Latest headlines on both assets
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →